Ann: Rexlemestrocel Reduces Heart Attacks/Strokes/CV Death in CHF, page-65

This announcement appears to contradict the original announcement in regard to the primary endpoint of non-fatal hospital visits.

This announcement states: 'Patients who received rexlemestrocel-L had a 68% reduction in the rate of recurrent hospitalizations from non-fatal heart attacks or strokes compared with controls'

The original announcement stated: 'Despite significant reduction inthe pre-specified endpoint of cardiac death, there was no reduction in recurrent non-fataldecompensated heart failure events, which was the trial’s primary endpoint. This suggests thatrexlemestrocel-L reduces mortality by mechanisms that are distinct from those of existing drugs thatreduce hospitalization rates but do not significantly impact cardiac mortality.'

I'm confused, did they stuff up the original announcement or stuff this one up?